Anti human ovarian cancer-anti CD3 bispecific antibody

Abstract

The present invention provides an anti-ovarian cancer bispecific antibody. Said antibody includes two polypeptide domains connected by a polypeptide linker, one is anti-ovarian cancer antibody, or its Fab fragment, single complementarity determining region (CDR) antibody or single chain Fv (scFv) and the other is anti-CD3 antibody, or its Fab fragment, single CDR antibody or scFv. The present invention also provides DNA sequences encoding said antibody, an expression vector containing said DNA sequence, and a host cell containing said expression vector.

1 .- 9 . (canceled) 
     
     
         10 . A DNA fragment comprising a nucleotide sequence encoding a bispecific antibody against ovarian cancer, said antibody comprising (i) an anti-ovarian cancer single chain antibody comprising a heavy chain variable region and a light chain variable region, said heavy chain variable region of said anti-ovarian cancer single chain antibody comprising the amino acid sequence as set forth in SEQ ID NO: 17, and said light chain variable region of said anti-ovarian cancer single chain antibody comprising the amino acid sequence as set forth in SEQ ID NO: 18: (ii) an anti-human CD3 single chain antibody; and (iii) an interlinker connecting said anti-ovarian cancer single chain antibody to said anti-human CD3 single chain antibody. 
     
     
         11 - 22 . (canceled) 
     
     
         23 . The DNA fragment of  claim 10 , wherein said anti-human CD3 single chain antibody of said bispecific antibody is a reshaped antibody. 
     
     
         24 . The DNA fragment of  claim 10 , wherein said heavy chain variable region of said anti-ovarian cancer single chain antibody and said light chain variable region of said anti-ovarian cancer single chain antibody, of said bispecific antibody, is connected by an intralinker comprising the amino acid sequence set forth in SEQ ID NO: 15. 
     
     
         25 . The DNA fragment of  claim 23 , wherein said heavy chain variable region of said anti-ovarian cancer single chain antibody and said light chain variable region of said anti-ovarian cancer single chain antibody, of said bispecific antibody, is connected by an intralinker comprising the amino acid sequence set forth in SEQ ID NO: 15. 
     
     
         26 . The DNA fragment of  claim 10 , wherein said anti-human CD3 single chain antibody of said bispecific antibody comprises a heavy chain variable region and a light chain variable region, said heavy chain variable region of said anti-human CD3 single chain antibody comprising the amino acid sequence set forth in SEQ ID NO: 19. 
     
     
         27 . The DNA fragment of  claim 10 , wherein said anti-human CD3 single chain antibody of said bispecific antibody comprises a heavy chain variable region and a light chain variable region, said light chain variable region of said anti-human CD3 single chain antibody comprising the amino acid sequence set forth in SEQ ID NO: 20. 
     
     
         28 . The DNA fragment of  claim 27 , wherein said heavy chain variable region of said anti-human CD3 single chain antibody of said bispecific antibody comprises the amino acid sequence set forth in SEQ ID NO: 19. 
     
     
         29 . The DNA fragment of  claim 28 , wherein the nucleotide sequence encoding said heavy chain variable region of said anti-ovarian cancer single chain antibody comprises SEQ ID NO: 1; the nucleotide sequence encoding said light chain variable region of said anti-ovarian cancer single chain antibody comprises SEQ ID NO: 3; the nucleotide sequence encoding said heavy chain variable region of said anti-human CD3 single chain antibody comprises SEQ ID NO: 5; and the nucleotide sequence encoding said light chain variable region of said anti-human CD3 single chain antibody comprises SEQ ID NO: 7. 
     
     
         30 . The DNA fragment of  claim 10 , wherein said interlinker of said bispecific antibody comprises the amino acid sequence set forth in SEQ ID NO: 23, SEQ ID NO: 25, or SEQ ID NO: 27. 
     
     
         31 . The DNA fragment of  claim 28 , wherein said interlinker of said bispecific antibody comprises the amino acid sequence set forth in SEQ ID NO: 23, SEQ ID NO: 25, or SEQ ID NO: 27. 
     
     
         32 . The DNA fragment of  claim 29 , wherein said interlinker of said bispecific antibody comprises the amino acid sequence set forth in SEQ ID NO: 23, SEQ ID NO: 25, or SEQ ID NO: 27. 
     
     
         33 . The DNA fragment of  claim 28  wherein said heavy chain variable region of said anti-ovarian cancer single chain antibody and said light chain variable region of said anti-ovarian cancer single chain antibody, of said bispecific antibody, is connected by an intralinker comprising the amino acid sequence set forth in SEQ ID NO: 15. 
     
     
         34 . The DNA fragment of  claim 33 , wherein said interlinker of said bispecific antibody comprises the amino acid sequence set forth in SEQ ID NO: 23, SEQ ID NO: 25, or SEQ ID NO: 27. 
     
     
         35 . The DNA fragment of  claim 33 , wherein the nucleotide sequence encoding said interlinker comprises the nucleotide sequence set forth in SEQ ID NO: 22, SEQ ID NO: 24, or SEQ ID NO: 26. 
     
     
         36 . The DNA fragment of  claim 10 , wherein said bispecific antibody further comprises a segment of six consecutive histidine residues. 
     
     
         37 . The DNA fragment of  claim 28 , wherein said bispecific antibody further comprises a segment of six consecutive histidine residues. 
     
     
         38 . The DNA fragment of  claim 34 , wherein said bispecific antibody further comprises a segment of six consecutive histidine residues. 
     
     
         39 . An expression vector comprising the DNA fragment of  claim 10 . 
     
     
         40 . An expression vector comprising the DNA fragment of  claim 28 . 
     
     
         41 . An expression vector comprising the DNA fragment of  claim 34 . 
     
     
         42 . An expression vector comprising the DNA fragment of  claim 37 . 
     
     
         43 . The expression vector, pAMAB or pTMAB.